Coloplast raises DKK 9.2 billion through directed share issue and private placement
Coloplast A/S successfully completed a directed issue and private placement of 12.2 million new B shares in an accelerated book-building process, raising gross proceeds of approximately DKK 9.2 billion. The new shares were subscribed for by Danish and international qualified institutional and other professional investors and certain other persons, including the Deputy Chairman and his family members. The directed issue was oversubscribed and an individual allocation was done.
Coloplast develops and manufactures intimate health care products that help people with private medical conditions improve their quality of life. Coloplast was founded in 1957 and is today a global leader in providing intimate health care services across its four divisions: Chronic Care, Wound & Skin Care, Interventional Urology, and Voice and Respiratory Care. Coloplast’s B shares are listed on Nasdaq Copenhagen A/S.
On 7 July 2023, Coloplast announced that it had completed the acquisition of Kerecis, a wound care group based in Iceland. The net proceeds from the private placement were used to pay for the purchase price of Kerecis.
Danske Bank A/S was the Sole Coordinator and, together with Nordea Danmark, Filial af Nordea Bank Abp, Finland, Jefferies GmbH and Morgan Stanley & Co International plc, the Joint Bookrunners in the private placement.
Contact
